EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)

Ieva Norkaityte, Laura Marija Racyte, Egle Balciunaite, Aiste Avizaite, Egle Zalyte

International Journal of Oncology · 08.10.2026 · 69 (5) · 1-20

DOI: 10.3892/ijo.2026.5945 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 08.10.2026. Verfasst von Ieva Norkaityte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Institute of Biosciences, Life Sciences Center, Vilnius University, LT‑10257 Vilnius, Lithuania. Hauptthemen laut MEDLINE: Active Transport, Cell Nucleus, Genital Neoplasms, Female, Antineoplastic Agents. Die Arbeit nennt 199 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proper localization of proteins and RNAs in a cell is crucial for physiological function and cellular homeostasis, while disruption of the nucleocytoplasmic transport machinery leads to carcinogenesis. In gynaecological (endometrial, cervical and ovarian) tumours, upregulated nuclear transport protein expression promotes malignant cell proliferation, invasion and resistance to therapy. Therefore, therapeutic targeting of nuclear transport proteins has emerged as a promising anticancer approach. Researchers have extensively studied both nuclear import and export inhibitors in preclinical settings, alone or in combination with other targeted therapy agents. However, to date, only one compound, the exportin 1 inhibitor Selinexor, has been approved for cancer treatment. The development of nuclear transport inhibition‑based therapies is hindered by limited inhibitor specificity and complex cellular resistance mechanisms. The aim of the present review was to clarify the connection between nuclear transport dysregulation, hallmarks of gynaecological tumours and the challenges of inhibiting nuclear transport in gynaecological cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Active Transport, Cell NucleusGenital Neoplasms, FemaleAntineoplastic AgentsHumansFemaleKaryopherinsExportin 1 ProteinTriazolesHydrazinesAnimalsReceptors, Cytoplasmic and NuclearCell NucleusCell Proliferation

Stichwörter der Autor:innen

cervical cancerendometrial cancernuclear transport inhibitorsnucleocytoplasmic transportovarian cancer

Substanzen

KaryopherinsExportin 1 ProteinAntineoplastic AgentsselinexorTriazolesHydrazinesReceptors, Cytoplasmic and Nuclear

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Institute of Biosciences, Life Sciences Center, Vilnius University, LT‑10257 Vilnius, Lithuania.
  • Laboratory of Molecular Oncology, National Cancer Institute, LT‑08406 Vilnius, Lithuania.
  • Faculty of Medicine, Vilnius University, LT‑03101 Vilnius, Lithuania.

Zitieren

APA

Norkaityte, I., Racyte, L. M., Balciunaite, E., Avizaite, A., & Zalyte, E. (2026). Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review). International Journal of Oncology, 69(5), 1-20. https://doi.org/10.3892/ijo.2026.5945

Vancouver

Norkaityte I, Racyte LM, Balciunaite E, Avizaite A, Zalyte E. Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review). International Journal of Oncology. 2026;69(5):1-20. doi:10.3892/ijo.2026.5945

BibTeX
@article{Norkaityte2026,
  author = {Norkaityte, Ieva and Racyte, Laura Marija and Balciunaite, Egle and Avizaite, Aiste and Zalyte, Egle},
  title = {Nucleocytoplasmic transport in gynaecological cancer: From mechanisms to therapeutic potential (Review)},
  journal = {International Journal of Oncology},
  year = {2026},
  volume = {69},
  number = {5},
  pages = {1--20},
  doi = {10.3892/ijo.2026.5945}
}
Kostenlos starten →